Marc F Botteman

7PUBLICATIONS
15CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Chemical and thermal processes in energy and combustionMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 11, 2021
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.

Rongzhe Liu, Olalekan O Oluwole, Ibrahim Diakite

|Nov 19, 2020
Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model.

Richard L Lindstrom, John P Berdahl, Eric D Donnenfeld

|Jul 30, 2020
Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.

Sandy Srinivas, Ateesha F Mohamed, Sreevalsa Appukkuttan

|Dec 15, 2019
Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.

Anuj Shah, Ruchit Shah, Nehemiah Kebede

|Jun 05, 2019
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.

Marc Botteman, Katharina Nickel, Shelby Corman

|May 17, 2019
Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.

Sang Hee Park, Gary Binder, Shelby Corman

Pageof 2

Frequent Collaborators

1 joint publications

Xinyi Ng

1 joint publications

Namita Joshi

1 joint publications

Richard L Lindstrom

1 joint publications

John P Berdahl